1879918-31-6

1879918-31-6 structure

Name: Loncastuximab tesirine
Chemical Name: Loncastuximab tesirine
CAS Number: 1879918-31-6
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2023-01-11 13:32:23
Modify Date: 2024-01-09 18:15:22
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell Apoptosis, it can be used for the research of diffuse large B-cell lymphoma[1][2].

Name	Loncastuximab tesirine

Description	Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell Apoptosis, it can be used for the research of diffuse large B-cell lymphoma[1][2].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer
In Vitro	Loncastuximab tesirine 降低了三种人源性 CD19 和 CD79b 阳性 NHL 细胞系 (WSU-DLCL2，TMD8 和 Ramos) 的细胞活力并诱导凋亡，与 polatuzumab vedotin 联合使用效果更好[1]。
In Vivo	Loncastuximab tesirine (0.25 或 0.5 mg/kg；单剂量) 在 WSU-DLCL2 异种移植物模型中显示抗肿瘤作用[1]。 Loncastuximab tesirine (0.33，0.66 和 1 mg/kg；单次静脉注射) 在 Ramos 异种移植模型中显示出剂量依赖的抗肿瘤活性[2]。 Loncastuximab tesirine (0.1 和 0.3 mg/kg；单次静脉注射) 在表达 CD19 的 Daudi 异种移植模型中显示出剂量依赖的抗肿瘤活性[2]。 Loncastuximab tesirine (0.3 和 1 mg/kg；单次静脉注射) 可显著延长 WSU-DLCL2 异种移植小鼠模型的生存期，且有剂量依赖性[2]。
References	[1]. Nikoleta Sachini, et al. Combination of Loncastuximab Tesirine and Polatuzumab Vedotin Shows Increased Anti-Tumor Activity in Pre-Clinical Models of Non-Hodgkin Lymphoma. Blood. 2021. [2]. Zammarchi F, et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018 Mar 8;131(10):1094-1105.

No Any Chemical & Physical Properties